JP2011518859A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011518859A5 JP2011518859A5 JP2011506691A JP2011506691A JP2011518859A5 JP 2011518859 A5 JP2011518859 A5 JP 2011518859A5 JP 2011506691 A JP2011506691 A JP 2011506691A JP 2011506691 A JP2011506691 A JP 2011506691A JP 2011518859 A5 JP2011518859 A5 JP 2011518859A5
- Authority
- JP
- Japan
- Prior art keywords
- benzodioxin
- methyl
- methylsulfonyl
- amine
- stereoisomers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 150000001204 N-oxides Chemical class 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 12
- -1 3,3,3-trifluoropropyl Chemical group 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 3
- PUQAQSKSJYGJLE-UHFFFAOYSA-N n-[(7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]ethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNCC)OCC2=C1 PUQAQSKSJYGJLE-UHFFFAOYSA-N 0.000 claims 3
- YKSJLFIAVRHURG-UHFFFAOYSA-N n-[(7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]propan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNCCC)OCC2=C1 YKSJLFIAVRHURG-UHFFFAOYSA-N 0.000 claims 3
- DQIMIWACWCCGFZ-UHFFFAOYSA-N n-methyl-1-(7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methanamine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNC)OCC2=C1 DQIMIWACWCCGFZ-UHFFFAOYSA-N 0.000 claims 3
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 208000004547 Hallucinations Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 230000010249 dopaminergic function Effects 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 230000000642 iatrogenic effect Effects 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- KAUHQTDTTDHUAJ-UHFFFAOYSA-N 1-(5-fluoro-7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)-n,n-dimethylmethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CN(C)C)OCC2=C1F KAUHQTDTTDHUAJ-UHFFFAOYSA-N 0.000 claims 1
- WBGIYAFUOWMNNS-UHFFFAOYSA-N 1-(5-fluoro-7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)-n-methylmethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNC)OCC2=C1F WBGIYAFUOWMNNS-UHFFFAOYSA-N 0.000 claims 1
- WTUDFSZPWQFVDO-UHFFFAOYSA-N 1-[(5-fluoro-7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]azetidine Chemical compound O1C2=CC(S(=O)(=O)C)=CC(F)=C2COC1CN1CCC1 WTUDFSZPWQFVDO-UHFFFAOYSA-N 0.000 claims 1
- GZYFJVSFYUFDCI-UHFFFAOYSA-N 1-[(5-fluoro-7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]piperidine Chemical compound O1C2=CC(S(=O)(=O)C)=CC(F)=C2COC1CN1CCCCC1 GZYFJVSFYUFDCI-UHFFFAOYSA-N 0.000 claims 1
- DIMPADLYPKZKIX-UHFFFAOYSA-N 1-[(5-fluoro-7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]pyrrolidine Chemical compound O1C2=CC(S(=O)(=O)C)=CC(F)=C2COC1CN1CCCC1 DIMPADLYPKZKIX-UHFFFAOYSA-N 0.000 claims 1
- OBLQSSWCGIJFIJ-UHFFFAOYSA-N 1-[(7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]azetidine Chemical compound O1C2=CC(S(=O)(=O)C)=CC=C2COC1CN1CCC1 OBLQSSWCGIJFIJ-UHFFFAOYSA-N 0.000 claims 1
- BDAKQXRCYNAIRC-UHFFFAOYSA-N 1-[(7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]piperidine Chemical compound O1C2=CC(S(=O)(=O)C)=CC=C2COC1CN1CCCCC1 BDAKQXRCYNAIRC-UHFFFAOYSA-N 0.000 claims 1
- URTABTHZAASNNB-UHFFFAOYSA-N 1-[(7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]pyrrolidine Chemical compound O1C2=CC(S(=O)(=O)C)=CC=C2COC1CN1CCCC1 URTABTHZAASNNB-UHFFFAOYSA-N 0.000 claims 1
- BQOYOAIMHRKLCO-UHFFFAOYSA-N 1-[[7-(trifluoromethylsulfonyl)-4h-1,3-benzodioxin-2-yl]methyl]pyrrolidine Chemical compound O1C2=CC(S(=O)(=O)C(F)(F)F)=CC=C2COC1CN1CCCC1 BQOYOAIMHRKLCO-UHFFFAOYSA-N 0.000 claims 1
- IOOMSAXDDYUHMI-UHFFFAOYSA-N 2-[(7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methylamino]ethanol Chemical compound C1OC(CNCCO)OC2=CC(S(=O)(=O)C)=CC=C21 IOOMSAXDDYUHMI-UHFFFAOYSA-N 0.000 claims 1
- SIZURZPTODVUEQ-UHFFFAOYSA-N 2-methoxy-n-[(7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]ethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNCCOC)OCC2=C1 SIZURZPTODVUEQ-UHFFFAOYSA-N 0.000 claims 1
- APTPDHYIBCGHGD-UHFFFAOYSA-N 3-fluoro-n-[(5-fluoro-7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]propan-1-amine Chemical compound C1OC(CNCCCF)OC2=CC(S(=O)(=O)C)=CC(F)=C21 APTPDHYIBCGHGD-UHFFFAOYSA-N 0.000 claims 1
- IDDXYZCGXDKVKF-UHFFFAOYSA-N 4-[(7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]morpholine Chemical compound O1C2=CC(S(=O)(=O)C)=CC=C2COC1CN1CCOCC1 IDDXYZCGXDKVKF-UHFFFAOYSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020852 Hypertonia Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- IFHVZASHIAVPSN-UHFFFAOYSA-N n,n-dimethyl-1-(7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methanamine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CN(C)C)OCC2=C1 IFHVZASHIAVPSN-UHFFFAOYSA-N 0.000 claims 1
- VKRNPXCFNACOML-UHFFFAOYSA-N n-[(5-fluoro-7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]-2,2-dimethylpropan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNCC(C)(C)C)OCC2=C1F VKRNPXCFNACOML-UHFFFAOYSA-N 0.000 claims 1
- VUDDJLGMMPKNNB-UHFFFAOYSA-N n-[(5-fluoro-7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]-2-methoxyethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNCCOC)OCC2=C1F VUDDJLGMMPKNNB-UHFFFAOYSA-N 0.000 claims 1
- AMMWXFDIXMLYFS-UHFFFAOYSA-N n-[(5-fluoro-7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]-2-methylpropan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNCC(C)C)OCC2=C1F AMMWXFDIXMLYFS-UHFFFAOYSA-N 0.000 claims 1
- ZKLBOHJDJLAYBE-UHFFFAOYSA-N n-[(5-fluoro-7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]-n-methylethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CN(C)CC)OCC2=C1F ZKLBOHJDJLAYBE-UHFFFAOYSA-N 0.000 claims 1
- SVZBDVHMYYSQEE-UHFFFAOYSA-N n-[(5-fluoro-7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]-n-propylpropan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CN(CCC)CCC)OCC2=C1F SVZBDVHMYYSQEE-UHFFFAOYSA-N 0.000 claims 1
- PLDSWMXSSQHKRQ-UHFFFAOYSA-N n-[(5-fluoro-7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]butan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNCCCC)OCC2=C1F PLDSWMXSSQHKRQ-UHFFFAOYSA-N 0.000 claims 1
- BSVGZUKCUIIBAQ-UHFFFAOYSA-N n-[(5-fluoro-7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]ethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNCC)OCC2=C1F BSVGZUKCUIIBAQ-UHFFFAOYSA-N 0.000 claims 1
- LSEMIOLJFFUTFI-UHFFFAOYSA-N n-[(5-fluoro-7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]prop-2-en-1-amine Chemical compound C1OC(CNCC=C)OC2=CC(S(=O)(=O)C)=CC(F)=C21 LSEMIOLJFFUTFI-UHFFFAOYSA-N 0.000 claims 1
- OCFXRUVONBCJDW-UHFFFAOYSA-N n-[(5-fluoro-7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]propan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNCCC)OCC2=C1F OCFXRUVONBCJDW-UHFFFAOYSA-N 0.000 claims 1
- XFEFNDTWTJWPSO-UHFFFAOYSA-N n-[(5-fluoro-7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]propan-2-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNC(C)C)OCC2=C1F XFEFNDTWTJWPSO-UHFFFAOYSA-N 0.000 claims 1
- UPXSYIVAEJHJAT-UHFFFAOYSA-N n-[(6-fluoro-7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]propan-1-amine Chemical compound FC1=C(S(C)(=O)=O)C=C2OC(CNCCC)OCC2=C1 UPXSYIVAEJHJAT-UHFFFAOYSA-N 0.000 claims 1
- KQTUBSCUDYMUNH-UHFFFAOYSA-N n-[(7-bromo-5-fluoro-4h-1,3-benzodioxin-2-yl)methyl]propan-1-amine Chemical compound C1=C(Br)C=C2OC(CNCCC)OCC2=C1F KQTUBSCUDYMUNH-UHFFFAOYSA-N 0.000 claims 1
- JXBYIYQKKSBUHX-UHFFFAOYSA-N n-[(7-bromo-6-fluoro-4h-1,3-benzodioxin-2-yl)methyl]propan-1-amine Chemical compound FC1=C(Br)C=C2OC(CNCCC)OCC2=C1 JXBYIYQKKSBUHX-UHFFFAOYSA-N 0.000 claims 1
- OTHIWSMLDDRNFR-UHFFFAOYSA-N n-[(7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]butan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNCCCC)OCC2=C1 OTHIWSMLDDRNFR-UHFFFAOYSA-N 0.000 claims 1
- ZNLJXDLKHNVXGY-UHFFFAOYSA-N n-[(7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]prop-2-en-1-amine Chemical compound C1OC(CNCC=C)OC2=CC(S(=O)(=O)C)=CC=C21 ZNLJXDLKHNVXGY-UHFFFAOYSA-N 0.000 claims 1
- HDYBLKSPXXIFKE-UHFFFAOYSA-N n-[(7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]propan-2-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CNC(C)C)OCC2=C1 HDYBLKSPXXIFKE-UHFFFAOYSA-N 0.000 claims 1
- BZPNYCBJWIXFFC-UHFFFAOYSA-N n-[[7-(trifluoromethyl)-4h-1,3-benzodioxin-2-yl]methyl]propan-1-amine Chemical compound C1=C(C(F)(F)F)C=C2OC(CNCCC)OCC2=C1 BZPNYCBJWIXFFC-UHFFFAOYSA-N 0.000 claims 1
- SDJGJEYLAMEICS-UHFFFAOYSA-N n-[[7-(trifluoromethylsulfonyl)-4h-1,3-benzodioxin-2-yl]methyl]ethanamine Chemical compound C1=C(S(=O)(=O)C(F)(F)F)C=C2OC(CNCC)OCC2=C1 SDJGJEYLAMEICS-UHFFFAOYSA-N 0.000 claims 1
- IYHZCCVTWNUMMW-UHFFFAOYSA-N n-[[7-(trifluoromethylsulfonyl)-4h-1,3-benzodioxin-2-yl]methyl]propan-1-amine Chemical compound C1=C(S(=O)(=O)C(F)(F)F)C=C2OC(CNCCC)OCC2=C1 IYHZCCVTWNUMMW-UHFFFAOYSA-N 0.000 claims 1
- RJOSJCIUHVFPIM-UHFFFAOYSA-N n-ethyl-n-[(5-fluoro-7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]ethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CN(CC)CC)OCC2=C1F RJOSJCIUHVFPIM-UHFFFAOYSA-N 0.000 claims 1
- PEYVCGMMXDVBBB-UHFFFAOYSA-N n-ethyl-n-[(5-fluoro-7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]propan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CN(CC)CCC)OCC2=C1F PEYVCGMMXDVBBB-UHFFFAOYSA-N 0.000 claims 1
- ICJHEQPBGPJNOS-UHFFFAOYSA-N n-ethyl-n-[(7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]ethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CN(CC)CC)OCC2=C1 ICJHEQPBGPJNOS-UHFFFAOYSA-N 0.000 claims 1
- ZUKBVEPHEWBHOY-UHFFFAOYSA-N n-methyl-n-[(7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]ethanamine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CN(C)CC)OCC2=C1 ZUKBVEPHEWBHOY-UHFFFAOYSA-N 0.000 claims 1
- BQDKJSPBQJOHHQ-UHFFFAOYSA-N n-methyl-n-[(7-methylsulfonyl-4h-1,3-benzodioxin-2-yl)methyl]propan-1-amine Chemical compound C1=C(S(C)(=O)=O)C=C2OC(CN(C)CCC)OCC2=C1 BQDKJSPBQJOHHQ-UHFFFAOYSA-N 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200800600 | 2008-04-29 | ||
| DKPA200800600 | 2008-04-29 | ||
| US4905708P | 2008-04-30 | 2008-04-30 | |
| US61/049,057 | 2008-04-30 | ||
| PCT/EP2009/055140 WO2009133110A1 (en) | 2008-04-29 | 2009-04-28 | Modulators of dopamine neurotransmission |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011518859A JP2011518859A (ja) | 2011-06-30 |
| JP2011518859A5 true JP2011518859A5 (cg-RX-API-DMAC7.html) | 2012-06-21 |
| JP5548853B2 JP5548853B2 (ja) | 2014-07-16 |
Family
ID=40937591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011506691A Expired - Fee Related JP5548853B2 (ja) | 2008-04-29 | 2009-04-28 | ドーパミン神経伝達のモジュレーター |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8492372B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2271638B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5548853B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102015674B (cg-RX-API-DMAC7.html) |
| AT (1) | ATE522515T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009242095A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2722986A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2271638T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2010011498A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009133110A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2271635A1 (en) * | 2008-04-29 | 2011-01-12 | NSAB, Filial af NeuroSearch Sweden AB, Sverige | Modulators of dopamine neurotransmission |
| US8524766B2 (en) | 2008-04-29 | 2013-09-03 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Modulators of dopamine neurotransmission |
| SG193992A1 (en) | 2011-04-19 | 2013-11-29 | Integrative Res Lab Sweden Ab | Novel modulators of cortical dopaminergic- and nmda-receptor-mediated glutamatergic neurotransmission |
| ES2663804T3 (es) * | 2013-12-12 | 2018-04-17 | Bio-Pharm Solutions Co., Ltd. | Compuestos derivados de sulfamato para su uso en el tratamiento o el alivio del dolor |
| CN106928147A (zh) * | 2017-03-14 | 2017-07-07 | 华东师范大学 | 三环二萜类似物及其制备方法、及其在制备抗前列腺癌药物中的应用 |
| CN113853369B (zh) | 2019-05-24 | 2025-08-22 | 爱尔兰790股份公司 | [2-(3-氟-5-甲磺酰基苯氧基)乙基](丙基)胺的药学上可接受的盐及其用途 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3058980A (en) | 1962-10-16 | Substitution products of benzo- | ||
| US2906757A (en) | 1959-09-29 | Their preparation | ||
| DE1110175B (de) | 1957-01-08 | 1961-07-06 | Rhone Poulenc Sa | Verfahren zur Herstellung von Benzodioxanderivaten |
| US3851062A (en) * | 1973-08-01 | 1974-11-26 | Minnesota Mining & Mfg | Method of suppressing weight gain |
| US4056540A (en) * | 1974-01-01 | 1977-11-01 | Bristol-Myers Company | 4-Phenyl-1,3-benzodioxans |
| US5189171A (en) | 1991-06-21 | 1993-02-23 | American Home Products Corporation | Antipsychotic benzodioxan derivatives |
| US5166367A (en) | 1991-06-21 | 1992-11-24 | American Home Products Corporation | Antipsychotic benzodioxan derivatives |
| US5126366A (en) | 1991-06-21 | 1992-06-30 | American Home Products Corporation | Aminophenoxyalkyl derivatives of benzodioxan |
| DE4135474A1 (de) | 1991-10-28 | 1993-04-29 | Bayer Ag | 2-aminomethyl-chromane |
| US5235055A (en) | 1992-09-02 | 1993-08-10 | American Home Products Corporation | Antipsychotic quinoline derivatives of benzodioxanmethylamine |
| US5245051A (en) | 1992-09-03 | 1993-09-14 | American Home Products Corporation | Antipsychotic chroman derivatives of benzodioxanmethylamine |
| WO1996038435A1 (en) | 1995-05-30 | 1996-12-05 | Abbott Laboratories | Dopamine agonists |
| US5663194A (en) | 1995-07-25 | 1997-09-02 | Mewshaw; Richard E. | Chroman-2-ylmethylamino derivatives |
| AR004229A1 (es) | 1995-11-06 | 1998-11-04 | Wyeth Corp | Derivados indolalquilo de benzodioxanmetilamina y su uso para preparar medicamentos |
| FR2791675B1 (fr) | 1999-03-30 | 2001-05-04 | Synthelabo | Derives de n-[2-(4-aminophenyl) ethyl] -2,3-dihydro-1,4- benzodioxinne-2-methanamine, leur preparation et leur application en therapeutique |
| SE9904723D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| GB0007376D0 (en) | 2000-03-28 | 2000-05-17 | Knoll Ag | Therapeutic agents |
| CA2461381A1 (en) | 2001-10-04 | 2003-04-10 | Wyeth | Chroman derivatives as 5-hydroxytryptamine-6 ligands |
| JP2007527412A (ja) | 2003-10-24 | 2007-09-27 | エグゼリクシス， インコーポレイテッド | Ｔａｏキナーゼモジュレーターおよび使用方法 |
| JP2007536302A (ja) | 2004-05-05 | 2007-12-13 | エフ．ホフマン−ラ ロシュ アーゲー | ５−ｈｔ６受容体、５−ｈｔ２ａ受容体、又はその両方の調節に有用なアリールスルホニルベンゾジオキサン類 |
| DE602005021641D1 (de) | 2004-06-08 | 2010-07-15 | Nsab, Filial Af Neurosearch Sweden Ab | Neue disubstituierte phenylpiperidine und piperazine als modulatoren der dopamin-neurotransmission |
| AR049646A1 (es) | 2004-06-16 | 2006-08-23 | Janssen Pharmaceutica Nv | Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados |
| MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| US7713954B2 (en) | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
| PE20061335A1 (es) | 2005-04-22 | 2006-12-29 | Wyeth Corp | Compuestos derivados de benzodioxano y benzodioxolano como moduladores del receptor 5-ht2c |
| SE529246C2 (sv) | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| US20070155824A1 (en) | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis |
| US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
| US8492431B2 (en) | 2005-12-19 | 2013-07-23 | Janssen Pharmaceutica, N.V. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity |
| US20070155827A1 (en) | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
| US20070155823A1 (en) | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents |
| US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
| US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
| WO2007120596A1 (en) | 2006-04-12 | 2007-10-25 | Wyeth | DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS |
| AR060493A1 (es) | 2006-04-18 | 2008-06-18 | Wyeth Corp | Derivados de benzodioxano y benzodioxolano. procesos de obtencion. |
| TW200812573A (en) | 2006-05-19 | 2008-03-16 | Janssen Pharmaceutica Nv | Co-therapy for the treatment of epilepsy and related disorders |
| TWI457122B (zh) | 2007-07-20 | 2014-10-21 | Orion Corp | 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物 |
| EP2271635A1 (en) | 2008-04-29 | 2011-01-12 | NSAB, Filial af NeuroSearch Sweden AB, Sverige | Modulators of dopamine neurotransmission |
| US8524766B2 (en) | 2008-04-29 | 2013-09-03 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Modulators of dopamine neurotransmission |
-
2009
- 2009-04-28 AU AU2009242095A patent/AU2009242095A1/en not_active Abandoned
- 2009-04-28 CA CA2722986A patent/CA2722986A1/en not_active Abandoned
- 2009-04-28 MX MX2010011498A patent/MX2010011498A/es active IP Right Grant
- 2009-04-28 WO PCT/EP2009/055140 patent/WO2009133110A1/en not_active Ceased
- 2009-04-28 CN CN200980115129.4A patent/CN102015674B/zh not_active Expired - Fee Related
- 2009-04-28 AT AT09738154T patent/ATE522515T1/de active
- 2009-04-28 EP EP09738154A patent/EP2271638B1/en not_active Not-in-force
- 2009-04-28 US US12/990,043 patent/US8492372B2/en not_active Expired - Fee Related
- 2009-04-28 JP JP2011506691A patent/JP5548853B2/ja not_active Expired - Fee Related
- 2009-04-28 DK DK09738154.5T patent/DK2271638T3/da active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011518858A5 (cg-RX-API-DMAC7.html) | ||
| RU2010141964A (ru) | Модуляторы дофаминовой нейротрансмиссии | |
| AU2002237654B2 (en) | Piperazine derivatives, their preparation and their use for treating central nervous system (CNS) disorders | |
| JP2011518859A5 (cg-RX-API-DMAC7.html) | ||
| RU2018130727A (ru) | Органические соединения | |
| WO2005079802A8 (en) | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | |
| UA88719C2 (ru) | Антагонисты рецепторов гистамина-3 | |
| WO2007105053A3 (en) | Tetralines antagonists of the h-3 receptor | |
| RU2009136592A (ru) | Терапевтические агенты | |
| WO2007063385A3 (en) | Spirocyclic amine histamine-3 receptor antagonists | |
| JP2002523508A5 (cg-RX-API-DMAC7.html) | ||
| AU2002237654A1 (en) | Piperazine derivatives, their preparation and their use for treating central nervous system (CNS) disorders | |
| CN101203216A (zh) | 二氢苯并呋喃衍生物及其用途 | |
| RU2011117927A (ru) | Карбаматное соединение или его соль | |
| JP2002523506A5 (cg-RX-API-DMAC7.html) | ||
| ATE482711T1 (de) | Kombinationsprodukt mit einem antagonisten oder inversen agonisten von histamine-rezeptor h3 und einem antipsychotischen oder antidepressiven mittel, und ihre verwendung zur herstellung eines medikaments zur verhinderung der nachteiligen wirkungen von psychotropika | |
| RU2314809C2 (ru) | Способ лечения депрессии соединениями-агонистами дельта-рецепторов | |
| RU2008148941A (ru) | 4-[(3-фторфенокси)фенилметил]пиперидин метансульфонат, применение, способ синтеза и фармацевтические композиции | |
| JP2011519839A5 (cg-RX-API-DMAC7.html) | ||
| CA2108967C (en) | Arylmorpholine, preparation and use | |
| KR20030053475A (ko) | 5-ｈｔ3 및 신경세포의 니코틴작용성 수용체 길항물질로서의 1-아미노-알킬시클로헥산 화합물을 이용한 치료방법 및 이 화합물을 함유하는 약학적 조성물 | |
| RU2007128080A (ru) | Производные пирролидиния в качестве мускариновых рецепторов мз | |
| RU2006122935A (ru) | Новые производные бензимидазола и имидазопиридина и их применение в качестве лекарственных средств | |
| JP6173693B2 (ja) | アリールピペラジンオピオイド受容体アンタゴニスト | |
| CA2616177C (en) | Imidazolylalkyl-pyridines for the treatment of a sleep disorder |